ReviewInternational journal of clinical oncology2023
Carcinogenesis and management of human papillomavirus-associated cervical cancer.
Review in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07306247 (Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical Low-grade Squamous Intraepithelial Lesions With HPV16/18 Infection), which is not on this map. Cited by 79 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical Low-grade Squamous Intraepithelial Lesions With HPV16/18 Infection
Who cites it
79 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Pooled it
- The correlation between vaginal pathogens and high-risk human papilloma virus infection: a meta-analysis of case-control studies.Frontiers in oncology · 2024Pooled it
- The characteristics of high-risk HPV-negative cervical cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study.Human vaccines & immunotherapeutics · 2026Article
- Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.Infectious diseases of poverty · 2026Article
- Human papillomavirus 18 E6-specific Affibody inhibits cervical cancer cell proliferation and induces apoptosis.Applied microbiology and biotechnology · 2026Article
- High-risk human papillomavirus positivity and associated factors among women living with HIV in public health facilities of Mekelle, Northern Ethiopia.Infectious agents and cancer · 2026Article
- HPV Infection and Oxidative Stress in Cervical Carcinogenesis: Linking Apoptosis, Senescence, SASP, and EMT.Antioxidants (Basel, Switzerland) · 2026Review
- Systemic Immune-Inflammation Markers Associate With Cervical Human Papillomavirus Infection in Asymptomatic Women.Open forum infectious diseases · 2026Article
- What If Trojan Horse Nanoparticles Could Change the Game for HPV Gene-Targeted Therapies?Journal of medical virology · 2026Review
- Article
- Cervicovaginal Microbiome Signatures Across Cervical Disease States: A Prospective Cross-Sectional Analysis.Diagnostics (Basel, Switzerland) · 2026Article
- Lack of molecular mimicry between HPV vaccine L1 antigen and human proteins by a computational analysis.International journal of clinical oncology · 2026Article
- Review
- Article
- Downregulation of HLA Class I Expression through HLA-A DNA Methylation Is Associated with Reduced CD8+ T-cell Infiltration in Cervical Cancer.Cancer immunology research · 2026Article
- Integrative molecular diagnostics for HPV-driven cervical carcinogenesis: a translational review of mechanisms and multimodal risk stratification.Frontiers in oncology · 2026Review
- Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.Oncology research · 2026Review
- Article
- Distribution of HPV genotypes and comparison of cervico-vaginal cytologies in PCR-detected HPV-positive patients: a retrospective observational study.Frontiers in global women's health · 2026Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical cancer to be eliminated. For the appropriate management of HPV-associated cervical cancer, it is important to understand the detailed mechanisms of cervical cancer development. First, the cellular origin of most cervical cancers is thought to be cells in the squamocolumnar junction (SCJ) of the uterine cervix. Therefore, it is important to understand the characteristics of SCJ for cervical cancer screening and treatment. Second, cervical cancer is caused by high risk HPV (HR-HPV) infection, however, the manner of progression to cervical cancer differs depending on the type of HR-HPV: HPV16 is characterized by a stepwise carcinogenesis, HPV18 is difficult to detect in precancerous lesions, and HPV52, 58 tends to remain in the state of cervical intraepithelial neoplasia (CIN). Third, in addition to the type of HPV, the involvement of the human immune response is also important in the progression and regression of cervical cancer. In this review, we demonstrate the carcinogenesis mechanism of HPV-associated cervical cancer, management of CIN, and the current treatment of CIN and cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.